Serono Genetics Institute S.a.

Genset S.a.

Genset

Other

Institut National De La Sante Et De La Recherche Medicale

Whitehead Institute for Biomedical Research

Bernard Bihain

Lydie Bougueleret

Frances Yen-Potin

Mary Erickson

Joachim Fruebis

Marta Blumenfeld

Ilya Chumakov

Daniel Cohen

Hiroaki Tanaka

Laurent Essioux

Frances Yen

Barbara A Chicca

Barbara Bour

Blake Denison

Jean-Baptiste Dumas Milne Edwards

Harvey F Lodish

Aymeric Duclert

Stephane Bejanin

Severin Jobert

Jean-Yves Giordano

Deno Dialynas

Catherine Clusel

Tom Chu

Aaron Scalia

John Chicca

Dana Ebbets-Reed

Luisa Salter-Cid

Tsu-Shuen Tsao

The present invention relates to antibodies specific for a receptor termed the Lipolysis Stimulated Receptor (LSR). Compositions comprising the antibodies are also provided.

Lipolysis stimulated receptor (LSR) specific antibodies

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. The application is related to OBG3 polypepide fragments and compositions comprising these fragments. It also discloses methods of reducing free fatty acid levels with the polypeptide fragments of the invention.

OBG3 globular head and uses thereof

The present invention is drawn to methods of screening for new compounds for the treatment of obesity and obesity-related diseases and disorders, as well as methods of treating obesity-related diseases and disorders, based on the discovery of the role of the leptin-LSR interaction in obesity.

Isolated polypeptide comprising a leptin fragment

The invention relates to polynucleotides of the PAPAP gene, polypeptides encoded by the PAPAP gene, and antibodies directed specifically against such polypeptides. The invention also concerns methods for the treatment or diagnosis of schizophrenia, bipolar disorder or related CNS disorder. The invention also concerns the interaction of PAPAP with schizophrenia candidate gene g34872.

Schizophrenia related protein

The present invention relates to the field of muscle research, in particular to the discovery of a compound effective for increasing muscle mass, muscle cell differentiation, and oxidation of free fatty acids in muscle, useful in methods of treating muscle-related diseases and disorders as well as for augmenting muscle mass in general. The muscle-related diseases or disorders envisaged to be treated by the methods of the invention include, but are not limited to, muscular dystrophy, and other conditions resulting in muscle atrophy or muscle wasting.

Use of Acrp30 globular head to promote increases in muscle mass and muscle differentiation

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. This application pertains to nucleic acids encoding a compound, globular OBG3 polypeptide fragments, vectors and transformed host cells containing these nucleic acids and methods of making the globular OBG3 polypeptide fragments.

Nucleic acids encoding OBG3 polypeptides

The invention concerns the human sbg1, g34665, sbg2, g35017 and g35018 genes, polynucleotides, polypeptides biallelic markers, and human chromosome 13q31-q33 biallelic markers. The invention also concerns the association established between schizophrenia and bipolar disorder and the biallelic markers and the sbg1, g34665, sbg2, g35017 and g35018 genes and nucleotide sequences. The invention provides means to identify compounds useful in the treatment of schizophrenia, bipolar disorder and related diseases, means to determine the predisposition of individuals to said disease as well as means for the disease diagnosis and prognosis.

Schizophrenia associated genes, proteins and biallelic markers

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GMG-3, GMG-4, Cluster 1, GMG-6A, or GMG-6B polypeptides have been identified that are beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing body mass and for treating metabolic-related diseases and disorders. These metabolic-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Metabolic gene polynucleotides and polypeptides and uses thereof

The present invention relates to the field of obesity research. Obesity is a public health problem that is serious and widespread. A compound, globular OBG3, has been identified that reduces weight gain in animals. This compound should be effective for reducing body mass and for treating obesity-related diseases and disorders. These obesity-related diseases and disorders include hyperlipidemias, atherosclerosis, diabetes, and hypertension.

Nucleic acids encoding OBG3 globular head and uses thereof

GMG-3 GMG-4 and GMG-6 polynucleotides and polypeptides and uses thereof

The present invention relates to a new complex receptor polypeptide LSR (Lipolysis Stimulated Receptor), characterized by its functional activities, the cloning of the cDNAs complementary to the messenger RNAs encoding each of the subunits of the multimeric complex, vectors and transformed cells, methods of diagnosis and of selection of compounds which can be used as medicament for the prevention and/or treatment of pathologies and/or of pathogeneses such as obesity and anorexia, hyperlipidemias, atherosclerosis, diabetes, hypertension, and more generally the various pathologies associated with abnormalities in the metabolism of cytokines.

LSR receptor, its activity, its cloning, and its applications to the diagnosis, prevention and/or treatment of obesity and related risks or complications

The present invention relates to the field of metabolic research. Metabolic disorders, such as obesity, are a public health problem that is serious and widespread. GSSP4 polypeptides have been identified that are believed to be beneficial in the treatment of metabolic disorders. These compounds should be effective for reducing cholesterol levels, body mass, body fat, and for treating metabolic-related diseases and disorders. The metabolic-related diseases or disorders include, but are not limited to, obesity, hyperlipidemia, hypercholesterolemia, atherosclerosis, diabetes, glucose intolerance, insulin resistance and hypertension.

GSSP4 polynucleotides and polypeptides and uses thereof

Methods and pharmaceutical compositions useful for treating obesity-related disorders using ApM-1 and related proteins.

Lipoprotein-regulating medicants

Schizophrenia related gene

The invention provides novel LSR genomic sequences, polypeptides, antibodies, and polynucleotides including biallelic markers derived from the LSR locus. Primers hybridizing to regions flanking these biallelic markers are also provided. This invention also provides polynucleotides and methods suitable for genotyping a nucleic acid containing sample for one or more biallelic markers of the invention. Further, the invention provides methods to detect a statistical correlation between a biallelic marker allele and a phenotype and/or between a biallelic marker haplotype and a phenotype.

Growing community of inventors

Cancale, France

Bernard Bihain